China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients

SHAOXING, China, May 8, 2026 /PRNewswire/ -- Recently, the novel oral BET inhibitor NHWD-870 HCI, independently developed by Zhejiang Wenda Pharmaceutical Technology Co., Ltd., officially received Breakthrough Therapy Designation from the China National Medical Products Administration...